ORCHIECTOMY AND ORCHIECTOMY PLUS MITOMYCIN C FOR METASTATIC PROSTATE CANCER IN PATIENTS WITH POOR PROGNOSIS:

医学 睾丸切除术 前列腺癌 泌尿科 前列腺 泌尿生殖系统 外科 丝裂霉素C 随机对照试验 癌症 肿瘤科 内科学
作者
Theo M. de Reijke,F. Keuppens,Peter Whelan,J. Kliment,M. R. G. Robinson,Lesley-Ann Rea,Richard Sylvester
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins]
卷期号:: 1658-1658 被引量:5
标识
DOI:10.1097/00005392-199911000-00023
摘要

The outcome of patients with symptomatic metastatic prostate cancer is poor and improved treatment regimens are urgently needed. Theoretically, the combination of orchiectomy and chemotherapy could reduce androgen sensitive and insensitive cells in the prostate. This European Organization for Research in Cancer Therapy Genitourinary Group randomized, multicenter phase III trial demonstrates the outcome of orchiectomy alone versus orchiectomy followed by intravenous mitomycin C.A total of 189 patients with metastatic prostate cancer and poor prognostic factors were randomized in this trial by 42 institutions. Of these patients 184 (97%) were eligible for study, including 90 treated with orchiectomy alone (orchiectomy only arm) and 94 treated with orchiectomy followed by 15 mg./m.2 mitomycin C in 1 week (combined treatment arm). Mitomycin C was administered every 6 weeks and treatment was continued as long as tolerance and patient compliance allowed, and no progression was observed. Objective and subjective criteria for progression were clearly defined in the protocol.Patient and tumor characteristics were well balanced between the 2 treatment arms. At a median followup of 4.2 years 144 patients had died, including 112 of prostate cancer. No significant differences for time to overall (p = 0.17), subjective (p = 0.25) and objective (p = 0.08) progression were found between the 2 treatment groups. For progression-free survival no difference was noted (p = 0.67) between the 2 treatment groups but a trend in favor of orchiectomy alone was observed for overall survival (p = 0.04). Mitomycin C induced considerable hematological, gastrointestinal, renal and pulmonary toxicity leading to discontinuation in 31% of patients with pulmonary toxicity and 7% with renal deterioration. In addition, the quality of life evaluation revealed significant reduction in the combined treatment arm.Based on the results of this randomized phase III study orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognostic factors cannot be recommended due to failure of improvement in survival and reduced quality of life parameters.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
韩麒嘉完成签到 ,获得积分10
1秒前
聪慧的凝海完成签到 ,获得积分0
10秒前
10秒前
wwb发布了新的文献求助10
13秒前
phil完成签到 ,获得积分10
13秒前
21秒前
高高菠萝完成签到 ,获得积分10
21秒前
滴滴滴完成签到 ,获得积分10
21秒前
yangsi完成签到 ,获得积分10
24秒前
量子星尘发布了新的文献求助10
25秒前
28秒前
酷炫葵阴发布了新的文献求助10
33秒前
ORANGE完成签到,获得积分10
35秒前
思源应助松松采纳,获得20
39秒前
共享精神应助酷炫葵阴采纳,获得10
41秒前
丝丢皮得完成签到 ,获得积分10
42秒前
43秒前
xfy完成签到,获得积分10
47秒前
阳炎完成签到,获得积分10
49秒前
行云流水完成签到,获得积分10
50秒前
51秒前
冷酷尔琴发布了新的文献求助10
55秒前
青水完成签到 ,获得积分10
59秒前
量子星尘发布了新的文献求助10
59秒前
59秒前
冷酷尔琴完成签到,获得积分10
59秒前
onevip完成签到,获得积分0
1分钟前
小莫完成签到 ,获得积分10
1分钟前
1分钟前
theseus完成签到,获得积分10
1分钟前
胡楠完成签到,获得积分10
1分钟前
北国雪未消完成签到 ,获得积分10
1分钟前
李振博完成签到 ,获得积分10
1分钟前
1分钟前
雪妮完成签到 ,获得积分10
1分钟前
松松发布了新的文献求助20
1分钟前
1分钟前
iwsaml完成签到 ,获得积分10
1分钟前
Caden完成签到 ,获得积分10
1分钟前
xmhxpz完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038029
求助须知:如何正确求助?哪些是违规求助? 3575740
关于积分的说明 11373751
捐赠科研通 3305559
什么是DOI,文献DOI怎么找? 1819224
邀请新用户注册赠送积分活动 892652
科研通“疑难数据库(出版商)”最低求助积分说明 815022